Jim Cramer on Merck & Co (MRK): ‘I’ve Got To Take a Hard Look At It’

Jim Cramer in a recent program on CNBC commented on Merck & Co Inc. (NYSE:MRK) earnings results and said the pharma giant’s report was among a series of statements from major companies that were “disappointing.”

“This is an earning season so far where a lot of the big ones that look like they’re just shockingly bad or disappointing—everyone knew. I mean, Merck reported a quarter, I think we all kind of knew that Keytruda had slowed down a little bit. We knew that there were some Gardasil problems.Winrevair, drug that they bought—pulmonary arterial hypertension—I thought it was terrific, 280 million. So I think that this is an example where you can just say, oh my god, damn, Merck down almost 40%. I got to—I, I, I got to take a hard look at it.”

GreensKeeper Asset Management stated the following regarding Merck & Co., Inc. (NYSE:MRK) in its Q3 2024 investor letter:

“Merck & Co., Inc. (NYSE:MRK) was our second-largest detractor this quarter, declining -8.3%. MRK’s leading HPV vaccine, GARDASIL 9, faced challenges internationally due to inventory buildup within its Chinese distributor, which is expected to reduce shipments for the remainder of 2024. Despite this short-term impact, the long-term outlook for GARDASIL 9 remains promising. Meanwhile, the company’s $27 billion Keytruda cancer juggernaut continues to grow at a healthy clip, powering earnings growth.”

While we acknowledge the potential of MRK as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than MRK and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.

Disclosure: None. This article is originally published at Insider Monkey.